Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC

Executive Summary

Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.

Advertisement

Related Content

Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register